• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Acceptance and commitment therapy not associated with different outcomes in patients with coronary artery disease

byPaary BalakumarandAlex Chan
June 20, 2024
in Cardiology, Chronic Disease, Psychiatry
Reading Time: 2 mins read
American Academy of Pediatrics recommends standards for adverse event disclosures
Share on FacebookShare on Twitter

1. Acceptance and Commitment Therapy in patients with coronary heart disease does not affect short-term biological indicators of risk but does improve psychological well-being timelines

Evidence Rating Level: 1 (Excellent)

This randomized controlled trial aimed to evaluate the efficacy of Acceptance and Commitment Therapy (ACT) on biological and psychological well-being of patients with coronary heart disease. The control group received the usual care (UC) of a 6-week multidisciplinary outpatient cardiac rehabilitation program which includes physical exercise, educational counselling, and medical exams. The experimental group received the same care with the addition of ACT given as 3 group sessions. Over the course of care, participants were tested for low-density lipoproteins (LDL), resting systolic blood pressure, body mass index, and a psychological well-being score (Psychological General Well-Being Index – PGWBI). Additionally, psychological inflexibility, dietary habits, exercise, smoking status and quality of life were assessed using questionnaires. Of the tested measures, the only significant change seen was a time effect seen in PGWBI. The study would have been improved with a larger sample size (n=92) though the heterogeneity in the population due to broad inclusion criteria means the results are more generalizable. Conducting the study with the UC as a control group is also a strength as other studies tend to compare to no treatment. A longer ACT duration should be done to investigate the effect of ACT length on outcomes.

Click to read the study in BMJ

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome

Chronic exposure to particulate matter is associated with increased cardiovascular risk

Universal Health Services acquisition of Talkspace connects virtual and inpatient behavioral care

Tags: cardiologychronic diseasepsychiatrypsychologytherapy
Previous Post

Heat exposure associated with increased myocardial blood flow

Next Post

Tris Pharma Creates Onyda XR: The First Liquid Non-stimulant Medication For ADHD.

RelatedReports

Chronic Disease

Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome

September 28, 2026
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Artificial Intelligence

Universal Health Services acquisition of Talkspace connects virtual and inpatient behavioral care

September 9, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
Next Post
Estrogen withdrawal associated with perimenopausal depression

Tris Pharma Creates Onyda XR: The First Liquid Non-stimulant Medication For ADHD.

#VisualAbstract: Osimertinib after Chemoradiotherapy Increases Survival in Stage III EGFR-Mutated NSCLC

#VisualAbstract: Osimertinib after Chemoradiotherapy Increases Survival in Stage III EGFR-Mutated NSCLC

General anesthesia exposure in infants not linked to impaired cognitive development

Total knee arthroplasty with MAKO robot assistance may improve surgical outcomes

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence (AI) capable of identifying uncommon gastrointestinal pathologies despite no targeted disease training
  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.